| (84) |
Designated Contracting States: |
|
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE
SI SK TR |
| (30) |
Priority: |
08.09.2005 US 714865 P
|
| (43) |
Date of publication of application: |
|
25.06.2008 Bulletin 2008/26 |
| (60) |
Divisional application: |
|
17159896.4 |
| (73) |
Proprietor: The Henry M. Jackson Foundation for the
Advancement of Military Medicine, Inc. |
|
Bethesda, MD 20817 (US) |
|
| (72) |
Inventors: |
|
- PONNIAH, Sathibalan
Columbia, MD 21044 (US)
- PEOPLES, George, E.
Fulton, MD 20759 (US)
- STORRER, Catherine, E.
Columbia, MD 21044 (US)
- FLORA, Michael
Mt. Airy, MD 21771 (US)
|
| (74) |
Representative: Steinecke, Peter et al |
|
Müller Fottner Steinecke
Rechtsanwalts- und Patentanwaltspartnerschaft mbB
Römerstrasse 16 b
52428 Jülich
52428 Jülich (DE) |
| (56) |
References cited: :
WO-A1-94/20127
US-A1- 2004 018 971
|
US-A- 5 726 023
US-B2- 7 179 645
|
|
| |
|
|
- KNUTSON K L ET AL: "Tumor antigen-specific T helper cells in cancer immunity and immunotherapy",
CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 54, no. 8, 1 August 2005
(2005-08-01) , pages 721-728, XP019333158, ISSN: 1432-0851, DOI: 10.1007/S00262-004-0653-2
- ABRAHAM MITTELMAN ET AL: "Monoclonal and polyclonal humoral immune response to EC
HER-2/NEU peptides with low similarity to the host's proteome", INTERNATIONAL JOURNAL
OF CANCER, vol. 98, no. 5, 10 April 2002 (2002-04-10) , pages 741-747, XP055111438,
ISSN: 0020-7136, DOI: 10.1002/ijc.10259
- DAKAPPAGARI N K ET AL: "Prevention of mammary tumors with a chimeric HER-2 B-cell
epitope peptide vaccine", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH,
US, vol. 60, no. 14, 15 July 2000 (2000-07-15) , pages 3782-3789, XP002290184, ISSN:
0008-5472
- RAMASAMY R ET AL: "Characterisation of an inhibitory monoclonal antibody-defined epitope
on a malaria vaccine candidate antigen", IMMUNOLOGY LETTERS, ELSEVIER BV, NL, vol.
23, no. 4, 1 February 1990 (1990-02-01), pages 305-309, XP023668953, ISSN: 0165-2478,
DOI: 10.1016/0165-2478(90)90077-4 [retrieved on 1990-02-01]
- WAGNER C ET AL: "Identification of an HLA-A*02 restricted immunogenic peptide derived
from the cancer testis antigen HOM-MEL-40/SSX2", CANCER IMMUNITY, ACADEMY OF CANCER
IMMUNOLOGY, CH, vol. 3, no. 18, 1 December 2003 (2003-12-01), pages 1-15, XP002486698,
ISSN: 1424-9634
- N. K. Dakappagari: "Conformational HER-2/neu B-cell epitope peptide vaccine designed
to incorporate two native disulfide bonds enhances tumor cell binding and antitumor
activities", Journal of Biological Chemistry, vol. 280, no. 1, 1 January 2004 (2004-01-01),
pages 54-63, XP055047782, US ISSN: 0021-9258, DOI: 10.1074/jbc.M411020200
- ZUM BUSCHENFELDE C M ET AL: "Antihuman Epidermal Growth Factor Receptor 2 (HER2) monoclonal
antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific
T lymphocytes against HER2-overexpressing tumor cells", CANCER RESEARCH, AMERICAN
ASSOCIATION FOR CANCER RESEARCH, US, vol. 62, no. 8, 15 April 2002 (2002-04-15) ,
pages 2244-2247, XP002981803, ISSN: 0008-5472
- KONO K ET AL: "Trastuzumab (Herceptin) Enhances Class I-restricted antigen presentation
Recognized by HER-2/neu-specific T Cytotoxic Lymphocytes", CLINICAL CANCER RESEARCH,
THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 10, no. 7, 1 April 2004 (2004-04-01),
pages 2538-2544, XP002981804, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-03-0424
|
|
